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Abstract
Purpose To explore the association between the 3,144 m/
z protein peak and the clinicopathological features and
prognosis in breast cancer.
Methods Using SELDI–TOF MS, we analyzed serum
protein peak at 3,144 m/z in 283 patients with node-posi-
tive breast cancer, its relationship with clinicopathological
features and their prognosis evaluating value of survival.
Results 3,144 m/z positive rate was higher in elderly
patients (42.8 % in C50-year-old vs. 31.2 % in \50,
P = 0.04). However, no correlation was observed between
3,144 m/z and other clinicopathological features (body
mass index, menstrual status, family history, TNM,
molecular subtypes, vascular invasion, neural invasion, p53
and CA15-3). However, the positive rate of 3,144 m/z was
higher than that of CA15-3 (35.5 vs. 11.4 %, McNemar v2
test, p\ 0.001). 3,144 m/z-negative patients (n = 177) had
a better 3-year overall survival (OS) than 3,144 m/z-posi-
tive patients (n = 106) (89.8 vs. 81.2 %, P = 0.045).
Younger patients (P = 0.016), postmenopausal status
(P = 0.019), small tumor (P\ 0.001), less positive nodes
(P\ 0.001), early stage (P\ 0.001), favorable molecular
subtype (P = 0.007), normal CA15-3 (P = 0.003) and
neoadjuvant chemotherapy (P = 0.001) predicted better
survival. Cox analysis showed that T3–4 (95 % CI
1.419–8.057, P = 0.006), lymph node metastasis (95 % CI
1.242–3.632, P = 0.006) and p53 mutation (95 % CI
1.088–6.378, P = 0.032) were independent adverse prog-
nostic factors. But childbirth C2 (95 % CI 0.163–0.986,
P = 0.046), adjuvant chemotherapy (95 % CI 0.062–0.921,
P = 0.038) and adjuvant radiotherapy (95 % CI
0.148–0.928, P = 0.034) were the independent factors in
reducing risk of death in breast cancer patients. Combination
testing of 3,144 m/z and CA15-3 will improve the prognosis
value of 3-year survival (P = 0.011); patients with
CA153-/3144- were characterized by the longest survival
(89.8 %) and the CA153?/3144? patients by the shortest.
Conclusions Serum protein peak at 3,144 m/z is a new
biomarker for breast cancer diagnosis and prognosis and
showed a higher positive rate than serum CA15-3. Com-
bining 3,144 m/z and CA15-3 testing may improve prog-
nosis of longer survival in breast cancer patients.
Keywords Breast cancer  Serum  SELDI–TOF MS 
3,144 m/z protein peak  CA15-3
Introduction
Breast cancer is one of the most common cancers in
women. Despite a good long-term overall survival, recur-
rence and metastasis are primarily responsible for treat-
ment failure [1]. Metastasis to the axillary lymph nodes is a
key indicator of prognosis in breast cancer. The overall
5-year survival of breast cancer patients with positive
axillary lymph node is lower than that of patients with
negative lymph nodes, and there is almost a linear
relationship between nodal disease burden and breast
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cancer-specific survival independent of tumor size.
Recently, breast cancer serum tumor markers for early
diagnosis, prognosis and recurrence monitoring have
received increasing attention [2, 3]. CA15-3 is a commonly
used marker in breast cancer management, and provides
assistance for advanced breast cancer diagnosis and mon-
itoring postoperative patients. However, the sensitivity of
CA15-3 for diagnosis of advanced breast cancer is only
15.3 [4] to 22.5 % [5]. Thus, there is an urgent need for a
simple, sensitive method for monitoring metastasis and
recurrence in breast cancer [6].
The human proteome reflects all proteins and peptides
which may be related to one gene and allows a more
detailed evaluation of disease status. At present, it has
become relatively easy to detect protein profiling in crude
biological samples with surface-enhanced laser desorption/
ionization time of flight mass spectrometry (SELDI–TOF
MS). Surface-enhanced laser desorption ionization time-of-
flight (SELDI–TOF) mass spectrometry (MS) is an inno-
vative approach in proteomics and has been used in the
clinical setting to study tumor protein biomarkers [7], seek
new markers for early diagnosis and prognosis in breast
cancer [8, 9], and identify a more sensitive marker for
neoadjuvant chemotherapy in breast cancer [10]. However,
only a few studies have attempted to identify new markers
for metastasis [11, 12], and few analyses have been per-
formed to study the relation between these markers and
breast cancer survival. We previously used SELDI–TOF
MS to analyze cell culture media and cell lysate from both
high- and low-metastatic human ovarian cancer cell lines,
and the results showed a differentially expressed protein
peak at 3,144 m/z between these cells. These findings were
preliminarily validated in serum samples from patients
with advanced ovarian cancer [13].
Searching the Swiss protein database using the TagIdent
online tool showed that a protein matched the 3,144 m/z
peak and that it probably was CD24, which is a glycosyl
phosphatidylinositol-anchored protein with mucin-like
adhesion. Lee et al. [14] reviewed CD24 expression
assessed by immunohistochemistry in 2,925 patients with
cancer from 28 research reports. They observed an elevated
expression of CD24 protein in a variety of cancers,
including ovarian, breast, bladder, gastrointestinal, endo-
metrial, bile duct, pancreatic, prostate and skin. CD24 may
be involved in tumor development through the promotion
of tumor cell proliferation, invasion and metastatic spread.
It has become a biomarker and prognostic indicator for
invasion and metastasis of certain malignant tumors [14].
Tissue CD24 expression levels may help to predict survival
in patients with breast cancer [15], but studies show that
highly invasive breast cancer cells often express CD44?/
CD24- [16]. Such cells are considered to be breast cancer
stem cells [17, 18].
So far, 3,144 m/z (CD24) expression in serum samples
from breast cancer patients with positive lymph nodes has not
been reported. This study aimed to analyze the protein peak at
3,144 m/z in serum samples from breast cancer patients with
positive lymph nodes to determine the association between
this protein peak and breast cancer prognosis, to evaluate its
clinical implications and guide future research.
Methods
Patients’ characteristics
We retrospectively studied breast cancer patients admitted to
the Zhejiang Cancer Hospital from August 2006 to June 2009.
Patients were enrolled if they had breast cancer with positive
lymph nodes. Diagnoses were established using surgical
biopsy specimens. Clinical classification was made according
to the Union for International Cancer Control (UICC) staging
system (2010 edition). TNM was defined as: T1, tumor size
B2 cm; T2, tumor size[2 andB5 cm; T3, tumor size[5 cm;
T4, regardless of tumor size, a direct invasion into the chest
wall (a) or skin (b); T4c = T4a ? T4b; T4d, inflammatory
breast cancer; N1, ipsilateral 1–3 lymph node positive; N2,
ipsilateral 4–9 lymph node positive; N3: ipsilateralC10 lymph
node positive or ipsilateral supraclavicular lymph node
metastasis; and M1, distant metastasis. Patients with metastatic
breast cancer and axillary lymph node metastasis from other
primary tumors were excluded. General demographic data,
pathological subtype, disease duration, and data on preopera-
tive and postoperative treatments were collected. The study
was approved by the ethics committee of Zhejiang Cancer
Hospital and informed consent was obtained from all patients.
A total of 283 women with node-positive breast cancer
with invasive ductal carcinoma after mastectomy were
enrolled. There were 115 premenopausal and 164 post-
menopausal women (4 patients had missing data) aged
from 25 to 75 years (median 49.0 years). Diagnoses for all
patients were confirmed by postoperative pathological
examination. There were 117 cases at stage II and 166
cases at stage III–IV.
The tumor molecular subtypes were: luminal A (ER? or
PR?, HER2-) in 134 patients, luminal B (ER? or PR?,
HER2?) in 39 patients, HER2 positive (ER-/PR-/
HER2?) in 33 patients and triple-negative or ‘‘basal-like’’
subtype (ER-/PR-/HER2-) in 72 patients. Five patients
had no immunohistochemistry record and the subtypes
were then unknown.
Laboratory instruments and reagents
We used a PBS IIc SELDI–TOF MS (Ciphergen Biosys-
tems, Fremont, CA, USA). Weak cation exchange (WCX)
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nanobeads, binding buffer and eluent products were pur-
chased from Saierdi Inc. (Beijing, China). Acetonitrile,
trifluoroacetic acid, SPA (sinapinic acid), urea, DTT,
CHAPS, Tris–HCl and pure H2O were purchased from
Sigma (St Louis, MI, USA).
Sample collection and testing
Sample collection and preparation
Before first treatment (surgery or neoadjuvant chemother-
apy), fasting peripheral blood samples were obtained from
all patients and immediately placed at 4 C for 1–2 h.
Serum was separated by centrifugation at 4,000 rpm, at
4 C for 5 min, and subsequently centrifuged at
14,000 rpm, at 4 C for 5 min, to remove residual cell
debris. Serum was transferred on ice to a new centrifuge
tube and stored at -80 C. Before testing, serum samples
were thawed on ice. Serum samples (10 ll) were pipetted
in 1.5 ml microcentrifuge tubes with 20 ll of 9 M urea
buffer (9 mol/l urea, 2 % CHAPS, 50 mmol/l Tris–HCl,
1 % DTT, pH 9.0). Diluted samples were allowed to reach
room temperature for 10 min, and 360 ll of binding buffer
was then added.
Measurement of protein peak at 3,144 m/z
The detailed procedure has been previously published [13].
Briefly, WCX nanobeads were transferred into PCR tubes
placed in a magnetic processor and liquid was removed.
Following addition of 100 ll binding buffer, the PCR tubes
were placed for 5 min in a magnetic processor to remove
liquid and the same procedure was repeated once. Diluted
serum sample (100 ll) was added to each PCR tube con-
taining nanobeads. After mixing and reaching room tem-
perature for 15 min, the PCR tubes were placed in the
magnetic processor for removing unbound sample. Binding
buffer (100 ll) was added to each tube; tubes were mixed
and let to react for 5 min. The PCR tubes were then placed
in the magnetic processor to discard liquid. The eluent
(10 ll) was added to each tube and tubes were placed in the
magnetic processor. 5 ll of supernatant was transferred to
another PCR tube amd 5 ll of saturated SPA solution
(sinapinic acid in 50 % acetonitrile and 0.5 % trifluoro-
acetic acid) was added and mixed well. Then, 1 ll was
spotted onto an Au chip and allowed to air dry.
Before the chip was read on the PBS IIc mass spec-
trometer, NP20 chip with all-in-one standard proteins was
used for instrument calibration, ensuring that the error in
molecular weight ranged less than 0.1 %. The parameters
of chip reading instrument were: laser intensity = 175;
detection sensitivity = 8; optimization range = 1,000–
15,000; and the highest molecular weight = 50,000. Each
point on the chip was collected 90 times. Data were col-
lected using the Ciphergen Protein Chip 3.2.1 software.
According to the ROC curve of the protein peak (3,144 m/z)
obtained from a previous study of pre-III–IV stage ovarian
cancer [7], when the boundary value was set at 1.15, the
sensitivity and specificity were 65.4 and 91.4 %, respec-
tively. Therefore, the current study in breast cancer defined
expression values of \1.15 as negative and of [1.15 as
positive.
CA15-3 testing standards
We tested the CA15-3 with the same fasting peripheral
blood samples as above. The Roche cancer antigen 15-3
(CA15-3) method is a sandwich electrochemiluminescence
immunoassay that employs a biotinylated monoclonal
CA15-3-specific antibody and a monoclonal CA15-3-spe-
cific antibody (Roche CA15-3 reagent, Roche Diagnostic
Corp). The normal reference value was 0–28 U/ml. CA15-
3 value over 28 U/ml was considered to be positive.
Tumor subtypes
Tumor subtypes were determined according to ER, PR and
HER2 using immunohistochemistry [19]. Four microme-
ters-thick sections of formalin-fixed, paraffin-embedded
tissue block of the best representative slide for each case
were prepared for immunostains. Estrogen receptor (ER—
monoclonal rabbit 1D5 clone), progesterone receptor
(PR—monoclonal mouse PR636 clone), HER2 (rabbit
immunoglobulin Hercep Test) and p53 (monoclonal mouse
DO-7 clone) were performed using FDA approved anti-
bodies. ER, PR and p53 were positive when C10 %. HER2
was positive (amplified/expressed) when 3? in [30 %
cells by immunohistochemistry. Cases with Hercep Test
2? score (equivocal) were further analyzed for HER2 gene
amplification by FISH (fluorescence in situ hybridization)
technique.
Follow-up
Follow-up was carried out in the outpatients receiving
postoperative treatment or by telephone interview. It was
completed on June 30, 2011.
Data analysis and statistics
Data were analyzed using SPSS 16.0 (SPSS Inc., Chicago,
IL, USA). Continuous data were described by frequency
and rate. Positive rates between the different clinical and
pathological features were examined using v2 tests. The
association between 3,144 m/z protein peak and p53 was
analyzed using McNemar v2 tests. Various factors affecting
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Table 1 Relationship between patients’ characteristics and 3,144 m/z protein expression
Protein peak at 3,144 m/z v2 P value
N Negative Positive Positive rate (%)
Age (years)
B50 151 104 47 31.1 5.537 0.019
[50 132 73 59 44.7
Blood type
O 96 58 38 39.6 2.914 0.405
A 97 64 33 34.0
B 67 38 29 43.3
AB 23 17 6 26.1
BMIa
\24 159 103 56 35.2 0.485 0.486
C24 117 71 46 39.3
Menstruationa (n = 279)
Premenopausal 115 66 49 42.6 3.087 0.079
Postmenopausal 164 111 53 32.3
Family historyb (n = 278)
Yes 65 45 20 30.8 1.281 0.258
No 213 131 82 38.5
Abortiona (n = 278)
No 179 111 68 38.0 0.597 0.440
Yes 99 66 33 33.3
Menarchea (years) (n = 277)
[15 120 79 41 34.2 0.343 0.558
B15 157 98 59 37.6
Childbirtha (n = 278)
C2 141 89 52 36.9 0.037 0.847
\2 137 88 49 35.8
Tumor size
T1–T2 233 145 88 37.8 0.055 0.815
T3–T4 50 32 18 36.0
Lymphovascular invasion
No 150 94 56 37.3 0.002 0.964
Yes 133 83 50 37.6
Neural invasion
No 249 154 95 38.2 0.430 0.512
Yes 34 23 11 32.4
Lymph node metastasis
N1 130 83 47 36.2 1.086 0.581
N2 86 50 36 41.9
N3 67 44 23 34.3
Clinical staging
Stage II 117 71 46 39.3 0.295 0.587
Stage III–IV 166 106 60 36.1
Subtypea (n = 278)
Luminal A 134 87 47 35.1 0.911 0.823
Luminal B 39 25 14 35.9
HER2 (?) 33 21 12 36.4
Basal-like 72 42 30 41.7
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survival were analyzed using the Kaplan–Meier method
and log-rank test. Meaningful variables and treatment data
from univariate analysis were introduced into a Cox
regression model to establish the independent prognostic
factors. A P value\0.05 was considered to be statistically
significant.
Results
Serum protein peak at 3,144 m/z and clinical features
The 3,144 m/z positive rate in the B50-year-old group was
31.1 % (47/151) and 44.7 % (59/132) in [50-year-old
(v2 = 5.537, P = 0.019). However, positive 3,144 m/z
was not correlated with patients’ body mass index, meno-
pausal status, family history, TNM stage, tumor molecular
subtypes, vascular invasion, neural invasion, p53 expres-
sion and CA15-3 (Table 1).
Serum protein peak at 3,144 m/z and prognosis
Follow-up was completed on June 30, 2011. 244 of 283
patients with breast cancer survived and 39 patients died.
The 3-year survival rate was 86.2 %. Kaplan–Meier sur-
vival analysis (Table 3) showed that the 3,144 m/z protein
peak was related with overall survival in breast cancer
patients. Positive protein expression at 3,144 m/z in 106
patients had a 3-year survival of 81.2 %, which was sig-
nificantly lower than that in 177 patients with negative
expression with a 3-year survival of 89.8 % (Log-Rank,
v2 = 4.403, P = 0.045) (Fig. 1). In univariate analyses,
the 3-year overall survival in breast cancer patients was
associated with age, menopausal status, tumor size, lymph
node metastasis, clinical stage, molecular typing, CA15-3,
3,144 m/z protein peak and neoadjuvant chemotherapy (all
P\ 0.05).
Cox regression analysis showed (Table 4) that T3–4,
lymph node metastasis, p53 mutation, childbirth, adjuvant
chemotherapy and radiotherapy were independent prog-
nostic factors in this group of patients with breast cancer.
The patients with T3–4 had 3.381-fold risk of death
compared with T12 patients (95 % CI 1.419–8.057,
P = 0.006); Cox proportional hazards model analysis
showed that the patients with N3 lymph node metastasis
had a 2.124-fold risk of death compared with patients with
N1 ? N2 lymph node metastasis (95 % CI 1.242–3.632,
P = 0.006). However, childbirth C2, adjuvant chemo-
therapy and adjuvant radiotherapy were the independent
factors in reducing the risk of death in breast cancer
patients. 3,144 m/z expression was not an independent
prognostic factor in patients with invasive ductal carci-
noma in our study.
Serum protein peak at 3,144 m/z and CA15-3
In 283 patients with breast cancer, 37.5 % (106/283) were
preoperatively detected with a positive protein peak at
3,144 m/z. Of these patients, 220 patients were tested for
CA15-3 and showed a positive result in 11.4 % (25/220).
The difference between the two methods was statistically
Table 1 continued
Protein peak at 3,144 m/z v2 P value
N Negative Positive Positive rate (%)
p53
Negative 109 72 37 33.9 4.382 0.112
Positive 147 93 54 36.7
Unknown 27 12 15 55.6
CA15-3a (n = 220)
Negative 195 124 71 36.4 0.685 0.408
Positive 25 18 7 28.0
BMI body mass index
a With missing data
b Any other family member with cancer
Table 2 Comparison of positive percentage between 3,144 m/z and
CA15-3
Protein peak at 3144 m/z Total
Negative Positive
CA15-3
Negative 124 (63.6) 71 (36.4) 195
Positive 18 (72.0) 7 (28.0) 25
Total 142 (64.5) 78 (35.5) 220
McNemar v2 test, P\ 0.001
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significant (McNemar v2 test, P\ 0.001), indicating that
the 3,144 m/z protein pattern in breast cancer patients had a
higher positive rate than the traditional CA15-3 marker.
Combination testing of 3,144 m/z and CA15-3 will
improve the prognosis value of 3-year survival (P = 0.011,
Fig. 2). Patients with CA153-/3,144- were characterized
Fig. 1 Kaplan–Meier estimates of overall survival for breast cancer
with 3144 m/z protein positive and negative
Table 3 Comparison of different breast cancer clinicopathological









B50 151 92.0 5.779 0.016
[50 132 79.8
Blood type





\24 159 86.4 0.009 0.926
C24 117 87.0
Menstruation
Premenopausal 115 79.5 5.478 0.019
Postmenopausal 164 91.3
Family historyb
Yes 65 87.3 0.110 0.741
No 213 85.1
Abortion
No 179 84.2 1.980 0.159
Yes 99 90.3
Menarchea (years)
[15 120 85.8 0.065 0.799
B15 157 86.7
Childbirtha
C2 141 88.6 2.075 0.150
\2 137 84.2
Tumor size
T1–T2 233 90.1 24.555 \0.001
T3–T4 50 67.6
Intravascular cancer embolus
No 150 86.6 0.398 0.528
Yes 133 85.8
Neural invasion
No 249 87.2 0.402 0.526
Yes 34 78.9
Lymph node metastasis




II 117 94.5 11.635 \0.001
III–IV 166 80.2
Subtypea
Luminal A 134 92.9 12.196 0.007
Luminal B 39 89.0











Negative 109 90.5 2.754 0.097
Positive 147 81.8
CA15-3a
Negative 195 89.9 8.94 0.003
Positive 25 65.3
Protein peak at 3,144 m/z
Negative 177 89.8 4.403 0.045
Positive 106 81.2
Neoadjuvant chemotherapy
No 128 78.0 11.071 0.001
Yes 155 93.0
Adjuvant chemotherapy
No 14 78.6 1.593 0.207
Yes 269 86.8
Adjuvant radiotherapy
No 128 84.7 0.674 0.412
Yes 155 87.3
BMI body mass index
a With missing data
b Any other family member with cancer
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by the longest survival (89.8 %) and CA153?/3,144?
patients by the shortest (53.6 %, Table 5).
Discussion
Over the past 30 years, the survival of women with early-
stage breast cancer has been prolonged [20]. In addition to
earlier detection, the use of adjuvant chemotherapy and
endocrine therapy following definitive surgery and radia-
tion therapy is credited with a significant improvement in
overall survival. Traditionally, the prognosis of breast
cancer has been known to be associated with tumor size,
nodal status, hormonal receptor status, histologic grade,
nuclear grade, human epidermal growth factor receptor 2
(HER2) expression, Ki-67 expression, etc. [21, 22]. How-
ever, positive axillary lymph node is a key indicator of
prognosis in breast cancer patients. In recent years, cancer
diagnostics has been taking enormous advantage of
genomics and proteomics, novel fields of modern biology.
Proteomics is the study of the proteome, which comprises
the complete protein components of the cell, tissue or
organism. The milestone paper, which was published in
2002 by the group of Petricoin and Liotta [23], showed that
components of the serum proteome identified by mass
spectrometry differentiated patients with ovarian cancer
from healthy individuals. Compared to diagnostic studies,
there were no satisfactory serum markers for early detec-
tion of the relapse of breast cancer after surgery and
adjuvant therapy, and few reports were seen with SELDI–
TOF MS being used in the prognosis for breast cancers
with varying conclusions.
The molecular difference was researched by the gene
microarray of breast cancer, and different gene expression
profiles were found, which were classified into basal-like
type, HER2 type, normal breast-like type and luminal-type.
Luminal-type breast cancer was characterized by profiles
of estrogen receptor (ER) positive or progesterone receptor
(PR) positive; it showed better prognosis than other sub-
types, such as basal-like type and HER2 type. In search of
these markers, investigators from our institutes and hospital
have published gene expression profiles in tumor tissue that
outperformed all prognostic parameters in predicting dis-
ease outcome. One of the proteomic technologies used
extensively in the search for novel markers is surface-
enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI–TOF MS). The proteome might have
greater ability in reflecting the molecular complexity of
breast cancer. Postoperative serum protein pattern may
provide prognostic information, since it reflects the host
response to metastasis. The candidate prognostic marker
found in the current study is most likely related to a
postoperative host response. In addition, as patients were
Fig. 2 Kaplan–Meier estimates of overall survival for breast cancer
with different CA153/3144 status
Table 4 COX multivariate
analysis of prognostic factors in
breast cancer patients
LN status N1, N2 and N3, CT
chemotherapy, RT radiotherapy
B SE Wald df Sig Exp(B) 95.0 % CI for Exp (B)
Lower Upper
T-stage 1.218 0.443 7.563 1 0.006 3.381 1.419 8.057
LN status 0.753 0.274 7.578 1 0.006 2.124 1.242 3.632
Childbirth C2 -0.915 0.460 3.964 1 0.046 0.401 0.163 0.986
p53 0.969 0.451 4.610 1 0.032 2.634 1.088 6.378
Adjuvant CT -1.427 0.686 4.325 1 0.038 0.240 0.062 0.921
Adjuvant RT -0.992 0.468 4.494 1 0.034 0.371 0.148 0.928










CA153?/3,144- 18 70.3 11.232 0.011
CA153-/3,144? 71 89.9
CA153-/3,144- 124 89.8
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treated with adjuvant chemotherapy, a post-treatment pat-
tern of differentially expressed proteins may represent
tumor phenotype and chemosensitivity. These proteins
produced during host response are generally present at
substantially higher circulatory concentrations than the
enzymes that process them upon their exposure to the
tumor microenvironment, so they can be detected in the
blood by SELDI–TOF MS.
This study used SELDI–TOF MS for detection of pro-
tein peak at 3,144 m/z in pretreatment peripheral blood
samples from 283 patients with breast cancer and lymph
node metastasis. There were no correlations between
positive rate of protein peak at 3,144 m/z and CA15-3 in
220 patients (Table 2). The positive rate of the protein peak
at 3,144 m/z (35.5 %) was significantly higher than that of
CA15-3 (11.4 %). Although the traditional CA15-3 tumor
marker has a low positive rate, the present study showed
that CA15-3-positive patients had a lower survival rate,
accompanied by other independent prognostic factors, thus
defining a poor prognosis in these patients. Positive CA15-
3 was mostly observed in patients at a late cancer stage. In
fact, the prognostic value of CA15-3 in advanced breast
cancer has already been appreciated [24]. However, there is
a lack of a sensitive marker for patients with early breast
cancer. To solve this problem, we conducted this study and
observed that the positive rate of 3,144 m/z protein peak in
lymph node metastasis and early stage breast cancer was
significantly higher than CA15-3, and that 3-year survival
rate of 107 patients with positive protein peak was signif-
icantly lower than the survival rate of 177 patients with
negative expression. Despite that univariate analyses sug-
gested a prognostic significance of 3,144 m/z protein peak,
multivariate analyses did not confirm its independent
prognostic value in breast cancer. But the combination
testing of 3,144 m/z and CA15-3 will improve the prog-
nosis value of 3-year survival (P = 0.011). The patients
with CA153-/3,144- were characterized by the longest
survival and the CA153?/3,144? patients by the shortest.
The 3,144 m/z protein peak is a new biomarker for
diagnosis and prognosis of breast cancer using peripheral
blood, which is an ideal test specimen, easy to obtain and
ready to be tested in various stages of the disease during
follow-up. Nevertheless, we should note that a large pro-
portion of the breast cancer patients with recurrence and
metastasis had normal serum biomarkers levels, and that
about 5 % of healthy people may have abnormal markers
[13]. Besides, there are obvious limitations of searching
proteins according to their molecular size, because some
proteins share the same molecular weight. Future research
should obtain sufficient data in highly metastatic human
breast cancer cells through some method for further char-
acterization of the protein at 3,144 m/z. The serum protein
peak detected at 3,144 m/z combined with CA15-3 may
provide a useful marker for diagnosis and prognosis of
breast cancer.
Molecular subtypes proposed by Goldhirsch et al. [19] at
the St Gallen International Breast Cancer Conference
(2011) were widely adopted. In-depth study of molecular
subtypes in breast cancer offers guidance on appropriate
and effective treatment management for clinicians, thus
avoiding inadequate treatment or overtreatment [25]. Cox
proportional hazards model showed that neoadjuvant che-
motherapy was an independent prognostic factor in breast
cancer patients and demonstrated that surgery supple-
mented with chemotherapy and radiotherapy can increase
survival. Cox proportional hazards model analysis showed
that neoadjuvant chemotherapy prior to surgery was a
prognostic factor, but did not reach statistical significance
in the multivariate analysis; further in-depth study is nee-
ded to clarify such difference [26].
The current study suffered from some drawbacks. For
example, chemotherapy, endocrine therapy and targeted
therapy were all included in chemotherapy, but a stratified
analysis will be performed in a future research. Also, a
study including a large number of patients is required to
confirm the prognostic significance of the 3,144 m/z pro-
tein peak.
In summary, the peripheral serum protein peak at
3,144 m/z provides an innovative, practical biomarker for
diagnosis and prognosis of breast cancer. The simultaneous
testing of serum CA15-3 may improve the detection rate of
patients with breast cancer and lymph node metastasis.
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